Bimagrumab
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
Eli Lilly · Phase 2 · Completed · Enrollment 507
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
- Placebo/30 mg/kg Bimagrumab
- 10/30 mg/kg Bimagrumab
- 30 mg/kg Bimagrumab
- Placebo + 1.0 mg Semaglutide
- Placebo + 2.4 mg Semaglutide
- 10 mg/kg Bimagrumab + 1.0 mg Semaglutide
- 10 mg/kg Bimagrumab + 2.4 mg Semaglutide
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo/30 mg/kg Bimagrumab | 40% | n/r | n/r | n/r |
| 10/30 mg/kg Bimagrumab | 58.1% | n/r | n/r | n/r |
| 30 mg/kg Bimagrumab | 97.7% | n/r | n/r | n/r |
| Placebo + 1.0 mg Semaglutide | 73.3% | n/r | n/r | n/r |
| Placebo + 2.4 mg Semaglutide | 92.2% | n/r | n/r | n/r |
| 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | 97.6% | n/r | n/r | n/r |
| 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | 100% | n/r | n/r | n/r |
| 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | n/r | n/r | n/r | n/r |
| 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | n/r | n/r | n/r | n/r |
Not shown
- 30 mg/kg Bimagrumab + 1.0 mg Semaglutide: endpoint not reported
- 30 mg/kg Bimagrumab + 2.4 mg Semaglutide: endpoint not reported